Geoffrey R. Oxnard, MD

Articles by Geoffrey R. Oxnard, MD

42 Tissue and Liquid Biopsy–Based Comprehensive Genomic Profiling Reveal Mechanisms of Therapy Resistance and Rare Targetable Alterations in Breast Cancer

ByEthan Sokol,Smruthy Sivakumar,Dexter X. Jin,Hanna Tukachinsky,Karthikeyan Murugesan,Dean Pavlick,Jeffrey S. Ross, MD,Garrett M. Frampton,Geoffrey R. Oxnard, MD,Priti S. Hegde

April 18th 2022

Use of Erlotinib or Gefitinib as Initial Therapy in Advanced NSCLC

ByGeoffrey R. Oxnard, MD,Vincent A. Miller, MD

April 30th 2010

Tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor receptor (EGFR), such as erlotinib (Tarceva) and gefitinib (Iressa), have shown remarkable activity in a portion of patients with non–small-cell lung cancer (NSCLC).

Latest Updated Articles

Use of Erlotinib or Gefitinib as Initial Therapy in Advanced NSCLC
April 30th 2010

Geoffrey R. Oxnard, MD

Articles by Geoffrey R. Oxnard, MD

42 Tissue and Liquid Biopsy–Based Comprehensive Genomic Profiling Reveal Mechanisms of Therapy Resistance and Rare Targetable Alterations in Breast Cancer

Use of Erlotinib or Gefitinib as Initial Therapy in Advanced NSCLC

Latest Updated Articles

Trending on CancerNetwork

Anthracycline Chemo May Accelerate Biological Aging in Breast Cancer Survivors

CELMoDs With CAR T-Cell Therapy and Bispecific Antibodies in Multiple Myeloma

Survival in Childhood and Adolescent Cancers Improves, but Racial Disparities Persist

What Sustained MRD Negativity Can Settle About Stopping Myeloma Maintenance

ASCENT-03: Sacituzumab Govitecan Versus Chemotherapy in First-Line Metastatic TNBC